Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions
Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?
0:32
Jul 15, 2025Cutaneous Melanoma

Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?

-

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?
2:01
Jul 15, 2025Cutaneous Melanoma

How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?

-

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?
2:33
Jul 15, 2025Cutaneous Melanoma

What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?

-

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?
1:10
Jul 15, 2025Cutaneous Melanoma

How can molecular diagnostics like MyPath reduce overtreatment in certain patients?

-

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?
1:35
Jul 15, 2025Cutaneous Melanoma

How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?

-

What are the limitations of GEP testing in melanoma diagnosis?
0:48
Jul 15, 2025Cutaneous Melanoma

What are the limitations of GEP testing in melanoma diagnosis?

-

Are GEP tests meant to replace or supplement traditional pathology for melanoma?
1:04
Jul 15, 2025Cutaneous Melanoma

Are GEP tests meant to replace or supplement traditional pathology for melanoma?

-

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?
1:43
Jul 15, 2025Cutaneous Melanoma

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?

-

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?
3:32
Jul 1, 2025Atopic Dermatitis

How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?

-

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?
2:03
Jul 1, 2025Atopic Dermatitis

Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?

-

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?
1:07
Jul 1, 2025Atopic Dermatitis

Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?

-

What is lebrikizumab's safety profile?
1:09
Jul 1, 2025Atopic Dermatitis

What is lebrikizumab's safety profile?

-

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?
2:06
Jul 1, 2025Atopic Dermatitis

How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?

-

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?
2:00
Jul 1, 2025Atopic Dermatitis

What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?

-

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong
1:17
Jul 1, 2025Atopic Dermatitis

What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong

-

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?
1:28
Jul 1, 2025Atopic Dermatitis

What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?

-

What are some limitations of traditional scoring/scaling systems in assessing AD severity?
2:47
Jul 1, 2025Atopic Dermatitis

What are some limitations of traditional scoring/scaling systems in assessing AD severity?

-

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?
2:17
Jul 1, 2025Atopic Dermatitis

How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?

-

Understanding the i31-SLNB Score: Moving Beyond Population Risk
0:25
Jul 1, 2025Skin Cancer

Understanding the i31-SLNB Score: Moving Beyond Population Risk

-

Risk Thresholds That Change Decisions: How to Read the i31-SLNB Score
1:01
Jul 1, 2025Skin Cancer

Risk Thresholds That Change Decisions: How to Read the i31-SLNB Score

-

Where This Matters Most: Applying i31-SLNB in Clinical Practice
1:24
Jul 1, 2025Skin Cancer

Where This Matters Most: Applying i31-SLNB in Clinical Practice

-

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?
0:40
Jul 1, 2025Skin Cancer

How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy?

-

What are common patient questions or concerns about this type of genomic testing?
1:26
Jul 1, 2025Skin Cancer

What are common patient questions or concerns about this type of genomic testing?

-

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?
1:42
Jul 1, 2025Skin Cancer

What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions?

-